Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 160 Lymphoid 82 Genitourinary 29 Myeloid 21 Breast 7 Sarcoma 6 Classical hematology 6 Gynecologic 4 Tumor-Agnostic 2 Plasma cell 2 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Everolimus 59 lutetium Lu 177 dotatate 46 Magnetic Resonance Spectroscopy 33 pembrolizumab 31 Temozolomide 31 Cisplatin 29 Nivolumab 26 Octreotide 24 lanreotide 23 cabozantinib 22 pasireotide 21 gallium Ga 68 dotatate 21 lenvatinib 20 Etoposide 19 Specimen Handling 18 Paclitaxel 18 Carboplatin 18 Capecitabine 18 Sunitinib 17 Bevacizumab 16 trametinib 15 dabrafenib 15 Doxorubicin 14 3-Iodobenzylguanidine 14 surufatinib 13 Sorafenib 13 Ipilimumab 13 Thyrotropin Alfa 12 Injections 12 Positron Emission Tomography Computed Tomography 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Mitoxantrone × Endocrine × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡